BRPI0608656A2 - composiÇÕes farmacÊuticas para tratamento de trombose - Google Patents
composiÇÕes farmacÊuticas para tratamento de trombose Download PDFInfo
- Publication number
- BRPI0608656A2 BRPI0608656A2 BRPI0608656-0A BRPI0608656A BRPI0608656A2 BR PI0608656 A2 BRPI0608656 A2 BR PI0608656A2 BR PI0608656 A BRPI0608656 A BR PI0608656A BR PI0608656 A2 BRPI0608656 A2 BR PI0608656A2
- Authority
- BR
- Brazil
- Prior art keywords
- chloro
- pharmaceutical composition
- benzimidazol
- patients
- carbonyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 68
- 208000007536 Thrombosis Diseases 0.000 title claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims abstract description 64
- 239000005557 antagonist Substances 0.000 claims abstract description 24
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 18
- 108010074860 Factor Xa Proteins 0.000 claims abstract description 17
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229920000669 heparin Polymers 0.000 claims abstract description 15
- 239000002319 fibrinogen receptor antagonist Substances 0.000 claims abstract description 14
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 13
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 13
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims abstract description 11
- 239000003868 thrombin inhibitor Substances 0.000 claims abstract description 11
- 229940123900 Direct thrombin inhibitor Drugs 0.000 claims abstract description 10
- 229940127215 low-molecular weight heparin Drugs 0.000 claims abstract description 10
- -1 hexyloxycarbonylamino-imino-methyl Chemical group 0.000 claims description 142
- 239000003112 inhibitor Substances 0.000 claims description 52
- 150000003839 salts Chemical class 0.000 claims description 45
- 108090000190 Thrombin Proteins 0.000 claims description 33
- 229960004072 thrombin Drugs 0.000 claims description 32
- 239000002253 acid Substances 0.000 claims description 26
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 claims description 18
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 18
- 229960003009 clopidogrel Drugs 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 15
- 238000013146 percutaneous coronary intervention Methods 0.000 claims description 14
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 12
- 150000004677 hydrates Chemical class 0.000 claims description 11
- 229930003448 Vitamin K Natural products 0.000 claims description 10
- 229940125782 compound 2 Drugs 0.000 claims description 10
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 10
- 239000011712 vitamin K Substances 0.000 claims description 10
- 235000019168 vitamin K Nutrition 0.000 claims description 10
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 10
- 229940046010 vitamin k Drugs 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 8
- 229960001138 acetylsalicylic acid Drugs 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000003981 vehicle Substances 0.000 claims description 8
- 206010047249 Venous thrombosis Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 239000012453 solvate Substances 0.000 claims description 7
- 239000005528 B01AC05 - Ticlopidine Substances 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 6
- 230000002537 thrombolytic effect Effects 0.000 claims description 6
- 229960005001 ticlopidine Drugs 0.000 claims description 6
- PHWBOXQYWZNQIN-UHFFFAOYSA-N ticlopidine Chemical compound ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 PHWBOXQYWZNQIN-UHFFFAOYSA-N 0.000 claims description 6
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 5
- 229920001499 Heparinoid Polymers 0.000 claims description 5
- 239000002554 heparinoid Substances 0.000 claims description 5
- 239000003055 low molecular weight heparin Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 3
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 229940025770 heparinoids Drugs 0.000 claims description 3
- 229960002137 melagatran Drugs 0.000 claims description 3
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 3
- 230000009861 stroke prevention Effects 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 230000001732 thrombotic effect Effects 0.000 claims description 3
- 229960001522 ximelagatran Drugs 0.000 claims description 3
- ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 claims description 3
- CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical compound NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 claims description 2
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims description 2
- 208000001435 Thromboembolism Diseases 0.000 claims description 2
- 229960003856 argatroban Drugs 0.000 claims description 2
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 229950003291 inogatran Drugs 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 208000009982 Ventricular Dysfunction Diseases 0.000 claims 1
- 229940118377 Vitamin antagonist Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229940124531 pharmaceutical excipient Drugs 0.000 claims 1
- 230000009424 thromboembolic effect Effects 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 230000006815 ventricular dysfunction Effects 0.000 claims 1
- 229940122388 Thrombin inhibitor Drugs 0.000 abstract description 2
- 229940019333 vitamin k antagonists Drugs 0.000 abstract description 2
- 229940122564 Factor X inhibitor Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 45
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 31
- 239000013543 active substance Substances 0.000 description 29
- 238000009472 formulation Methods 0.000 description 21
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 15
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 12
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 11
- 238000001727 in vivo Methods 0.000 description 10
- 239000002585 base Substances 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 6
- QPBGBSDWBAQHTP-UHFFFAOYSA-N N-benzoyl-2,5-dihydropyrrole-1-carboxamide Chemical compound C(C1=CC=CC=C1)(=O)NC(=O)N1CC=CC1 QPBGBSDWBAQHTP-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 229940098779 methanesulfonic acid Drugs 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- CDCHBOQVXIGZHA-UHFFFAOYSA-N 1,2-dihydropyrrol-5-one Chemical compound O=C1NCC=C1 CDCHBOQVXIGZHA-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 229940099112 cornstarch Drugs 0.000 description 4
- 125000001841 imino group Chemical group [H]N=* 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000011976 maleic acid Chemical class 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 235000002906 tartaric acid Nutrition 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 150000001447 alkali salts Chemical class 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 229940125904 compound 1 Drugs 0.000 description 3
- 229960000610 enoxaparin Drugs 0.000 description 3
- 229960001318 fondaparinux Drugs 0.000 description 3
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 description 3
- 239000001530 fumaric acid Chemical class 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 159000000001 potassium salts Chemical class 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 159000000000 sodium salts Chemical class 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000011975 tartaric acid Substances 0.000 description 3
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical compound C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 description 3
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 2
- OFJRNBWSFXEHSA-UHFFFAOYSA-N 2-(3-amino-1,2-benzoxazol-5-yl)-n-[4-[2-[(dimethylamino)methyl]imidazol-1-yl]-2-fluorophenyl]-5-(trifluoromethyl)pyrazole-3-carboxamide Chemical compound CN(C)CC1=NC=CN1C(C=C1F)=CC=C1NC(=O)C1=CC(C(F)(F)F)=NN1C1=CC=C(ON=C2N)C2=C1 OFJRNBWSFXEHSA-UHFFFAOYSA-N 0.000 description 2
- MUDDBYBUHQHBRH-UHFFFAOYSA-N 2-(pyrrolidine-1-carbonyl)benzamide Chemical compound NC(=O)C1=CC=CC=C1C(=O)N1CCCC1 MUDDBYBUHQHBRH-UHFFFAOYSA-N 0.000 description 2
- HGWPBTGFBUCYDA-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-(2-hydroxyethyl)butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)NCCO)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 HGWPBTGFBUCYDA-UHFFFAOYSA-N 0.000 description 2
- TUEGSDGZOVSICV-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-(2-methoxyethyl)butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)NCCOC)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 TUEGSDGZOVSICV-UHFFFAOYSA-N 0.000 description 2
- SRQBXGREFBIHPK-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-cyclopentylbutanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NC1CCCC1 SRQBXGREFBIHPK-UHFFFAOYSA-N 0.000 description 2
- MAUOWUDOVCSFNL-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-cyclopropylbutanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NC1CC1 MAUOWUDOVCSFNL-UHFFFAOYSA-N 0.000 description 2
- ALKOINOBWCYBTA-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-methyl-n-[2-(methylamino)-2-oxoethyl]butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)N(C)CC(=O)NC)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 ALKOINOBWCYBTA-UHFFFAOYSA-N 0.000 description 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
- 102100034213 ATPase family protein 2 homolog Human genes 0.000 description 2
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 108010056764 Eptifibatide Proteins 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- HPHBHDUSVYOGTD-QRWLVFNGSA-N [(2r)-2-(aminomethyl)pyrrolidin-1-yl]-[6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfonylpropyl]amino]quinazolin-7-yl]methanone Chemical compound N([C@@H](CCS(=O)(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCC[C@@H]1CN HPHBHDUSVYOGTD-QRWLVFNGSA-N 0.000 description 2
- QDEWTQJURKBCOQ-IBGZPJMESA-N [4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]-6-methoxyquinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound COC1=CC2=C(N[C@@H](CCSC)C=3NC4=CC=C(Cl)C=C4N=3)N=CN=C2C=C1C(=O)N1CC=CC1 QDEWTQJURKBCOQ-IBGZPJMESA-N 0.000 description 2
- XGBHUMKSNKSZNX-AWEZNQCLSA-N [4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]-6-methylquinazolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2C)=NC=NC1=CC=2C(=O)N1CCCC1 XGBHUMKSNKSZNX-AWEZNQCLSA-N 0.000 description 2
- RQHGXOYKVGDQRP-IBGZPJMESA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@@H](CCSC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 RQHGXOYKVGDQRP-IBGZPJMESA-N 0.000 description 2
- 229960000446 abciximab Drugs 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 229960003886 apixaban Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- 229940050390 benzoate Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- CZKPOZZJODAYPZ-LROMGURASA-N eptifibatide Chemical compound N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCCNC(=N)N)NC(=O)CCSSC[C@@H](C(N)=O)NC(=O)[C@@H]2CCCN2C(=O)[C@@H]1CC1=CNC2=CC=CC=C12 CZKPOZZJODAYPZ-LROMGURASA-N 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- VYNKVNDKAOGAAQ-RUZDIDTESA-N n-[(1r)-2-[4-(1-methylpiperidin-4-yl)piperazin-1-yl]-2-oxo-1-phenylethyl]-1h-indole-6-carboxamide Chemical compound C1CN(C)CCC1N1CCN(C(=O)[C@H](NC(=O)C=2C=C3NC=CC3=CC=2)C=2C=CC=CC=2)CC1 VYNKVNDKAOGAAQ-RUZDIDTESA-N 0.000 description 2
- SXZNYIIOWDSYJU-UHFFFAOYSA-N n-[1-(6-chloro-1h-benzimidazol-2-yl)ethyl]-4-(2,5-dihydropyrrole-1-carbonyl)-3-methylbenzamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(C)NC(=O)C(C=C1C)=CC=C1C(=O)N1CC=CC1 SXZNYIIOWDSYJU-UHFFFAOYSA-N 0.000 description 2
- OPHHHQALEOSQKW-UHFFFAOYSA-N n-benzoylpyrrolidine-1-carboxamide Chemical compound C1CCCN1C(=O)NC(=O)C1=CC=CC=C1 OPHHHQALEOSQKW-UHFFFAOYSA-N 0.000 description 2
- MVPQUSQUURLQKF-MCPDASDXSA-E nonasodium;(2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3s,4s,5r,6r)-2-carboxylato-4,5-dimethoxy-6-[(2r,3r,4s,5r,6s)-6-methoxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-disulfonatooxy-2-(sulfonatooxymethyl)oxan-3-yl]oxy-4,5-di Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[O-]S(=O)(=O)O[C@@H]1[C@@H](OS([O-])(=O)=O)[C@@H](OC)O[C@H](COS([O-])(=O)=O)[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@@H]2[C@@H]([C@@H](OS([O-])(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](OC)[C@H](O[C@@H]4[C@@H]([C@@H](OC)[C@H](OC)[C@@H](COS([O-])(=O)=O)O4)OC)[C@H](O3)C([O-])=O)OC)[C@@H](COS([O-])(=O)=O)O2)OS([O-])(=O)=O)[C@H](C([O-])=O)O1 MVPQUSQUURLQKF-MCPDASDXSA-E 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- KMYNUYSFASSQBX-UHFFFAOYSA-N pyrrolidin-1-yl(quinazolin-2-yl)methanone Chemical compound N=1C=C2C=CC=CC2=NC=1C(=O)N1CCCC1 KMYNUYSFASSQBX-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 229960005496 reviparin Drugs 0.000 description 2
- KGFYHTZWPPHNLQ-AWEZNQCLSA-N rivaroxaban Chemical compound S1C(Cl)=CC=C1C(=O)NC[C@@H]1OC(=O)N(C=2C=CC(=CC=2)N2C(COCC2)=O)C1 KGFYHTZWPPHNLQ-AWEZNQCLSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 108010091193 spermatogenesis associated factor Proteins 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229960003425 tirofiban Drugs 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- DEJXXVQJMXTPLQ-SFHVURJKSA-N (4s)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoic acid Chemical compound N([C@@H](CCC(=O)O)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 DEJXXVQJMXTPLQ-SFHVURJKSA-N 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- DMDZXHOBZWZWMI-UHFFFAOYSA-N 2-(3-carbamimidoylphenyl)-2-methyl-n-[3-methyl-4-(pyrrolidine-1-carbonyl)phenyl]propanamide Chemical compound C=1C=C(C(=O)N2CCCC2)C(C)=CC=1NC(=O)C(C)(C)C1=CC=CC(C(N)=N)=C1 DMDZXHOBZWZWMI-UHFFFAOYSA-N 0.000 description 1
- ACFLXQIWOZPFDW-UHFFFAOYSA-N 2-(5-carbamimidoyl-2-hydroxyphenyl)-3-phenyl-N-[4-(pyrrolidine-1-carbonyl)-3-(trifluoromethyl)phenyl]propanamide Chemical compound NC(=N)C1=CC=C(O)C(C(CC=2C=CC=CC=2)C(=O)NC=2C=C(C(C(=O)N3CCCC3)=CC=2)C(F)(F)F)=C1 ACFLXQIWOZPFDW-UHFFFAOYSA-N 0.000 description 1
- WTPPUXIHAAIFEF-UHFFFAOYSA-N 2-(5-carbamimidoyl-2-hydroxyphenyl)-N-[3-methyl-4-(pyrrolidine-1-carbonyl)phenyl]acetamide Chemical compound C=1C=C(C(=O)N2CCCC2)C(C)=CC=1NC(=O)CC1=CC(C(N)=N)=CC=C1O WTPPUXIHAAIFEF-UHFFFAOYSA-N 0.000 description 1
- BLGQROIGCHBMQP-UHFFFAOYSA-N 2-(aminomethyl)benzenecarboximidamide Chemical compound NCC1=CC=CC=C1C(N)=N BLGQROIGCHBMQP-UHFFFAOYSA-N 0.000 description 1
- MAOALPSHCIBFJZ-RUZDIDTESA-N 2-[[(2r)-2-[2-[[4-[amino(azaniumylidene)methyl]anilino]methyl]-1-methylbenzimidazol-5-yl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]amino]acetate Chemical compound N=1C2=CC([C@@](C)(NCC(O)=O)C(=O)N3CCCC3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 MAOALPSHCIBFJZ-RUZDIDTESA-N 0.000 description 1
- ZHXGXULYUZVCBR-UHFFFAOYSA-N 2-[[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazol-5-yl]-quinolin-8-ylsulfonylamino]acetic acid Chemical compound N=1C2=CC(N(CC(O)=O)S(=O)(=O)C=3C4=NC=CC=C4C=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 ZHXGXULYUZVCBR-UHFFFAOYSA-N 0.000 description 1
- UDXBFVFGUYSOME-UHFFFAOYSA-N 2-[[2-[2-[(4-carbamimidoylanilino)methyl]-1-methylbenzimidazol-5-yl]-2-methyl-3-oxo-3-pyrrolidin-1-ylpropyl]amino]acetic acid Chemical compound N=1C2=CC(C(C)(CNCC(O)=O)C(=O)N3CCCC3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 UDXBFVFGUYSOME-UHFFFAOYSA-N 0.000 description 1
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- ZMPRRFPMMJQXPP-UHFFFAOYSA-N 2-sulfobenzoic acid Chemical class OC(=O)C1=CC=CC=C1S(O)(=O)=O ZMPRRFPMMJQXPP-UHFFFAOYSA-N 0.000 description 1
- DMJDEZUEYXVYNO-UHFFFAOYSA-N 3-(4-phenylphenyl)prop-2-enoic acid Chemical compound C1=CC(C=CC(=O)O)=CC=C1C1=CC=CC=C1 DMJDEZUEYXVYNO-UHFFFAOYSA-N 0.000 description 1
- UGEWTLXHMYKLCO-UHFFFAOYSA-N 3-[[2-[[4-[(e)-n'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoic acid Chemical compound C1=CC(C(=N)NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N1C UGEWTLXHMYKLCO-UHFFFAOYSA-N 0.000 description 1
- OUUHCFQNWCARFH-UHFFFAOYSA-N 3-[[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]methyl]-4-hydroxybenzenecarboximidamide Chemical compound NC(=N)C1=CC=C(O)C(CNC=2C3=CC(Cl)=C(C(=O)N4CCCC4)C=C3N=CN=2)=C1 OUUHCFQNWCARFH-UHFFFAOYSA-N 0.000 description 1
- YRGZMEPXUSMUPP-IBGZPJMESA-N 3-bromo-n-[(1r)-1-(6-bromo-1h-benzimidazol-2-yl)-2-methoxyethyl]-4-(2,5-dihydropyrrole-1-carbonyl)benzamide Chemical compound N([C@@H](COC)C=1NC2=CC=C(Br)C=C2N=1)C(=O)C(C=C1Br)=CC=C1C(=O)N1CC=CC1 YRGZMEPXUSMUPP-IBGZPJMESA-N 0.000 description 1
- INEYFUQRZLZMFK-NRFANRHFSA-N 3-bromo-n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-prop-2-ynoxyethyl]-4-(2,5-dihydropyrrole-1-carbonyl)benzamide Chemical compound N([C@@H](COCC#C)C=1NC2=CC=C(C=C2N=1)Cl)C(=O)C(C=C1Br)=CC=C1C(=O)N1CC=CC1 INEYFUQRZLZMFK-NRFANRHFSA-N 0.000 description 1
- RWTQYKUONPWEES-UHFFFAOYSA-N 3-chloro-n-[(6-chloro-1h-benzimidazol-2-yl)methyl]-4-(3-oxopiperazine-1-carbonyl)benzamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1CNC(=O)C(C=C1Cl)=CC=C1C(=O)N1CCNC(=O)C1 RWTQYKUONPWEES-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- UPJWBQXETHABOR-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-1-(4-hydroxypiperidin-1-yl)butan-1-one Chemical compound C1CC(O)CCN1C(=O)CCC(C=1NC2=CC=C(Cl)C=C2N=1)NC1=NC=NC2=CC(C(=O)N3CCCC3)=C(Cl)C=C12 UPJWBQXETHABOR-UHFFFAOYSA-N 0.000 description 1
- MVGLQCNJKHVLGH-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-1-(4-methylpiperazin-1-yl)butan-1-one Chemical compound C1CN(C)CCN1C(=O)CCC(C=1NC2=CC(Cl)=CC=C2N=1)NC1=NC=NC2=CC(C(=O)N3CCCC3)=C(Cl)C=C12 MVGLQCNJKHVLGH-UHFFFAOYSA-N 0.000 description 1
- KTOSDBDBNCWIKN-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-1-morpholin-4-ylbutan-1-one Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)N1CCOCC1 KTOSDBDBNCWIKN-UHFFFAOYSA-N 0.000 description 1
- GDIKJXXZRARNKX-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n,n-diethylbutanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)N(CC)CC)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 GDIKJXXZRARNKX-UHFFFAOYSA-N 0.000 description 1
- FZMLWCDQELFMQZ-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-(cyclopropylmethyl)-n-methylbutanamide Chemical compound N=1C=NC2=CC(C(=O)N3CCCC3)=C(Cl)C=C2C=1NC(C=1NC2=CC=C(Cl)C=C2N=1)CCC(=O)N(C)CC1CC1 FZMLWCDQELFMQZ-UHFFFAOYSA-N 0.000 description 1
- SDHGNNCYCXUKTQ-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-(oxan-4-ylmethyl)butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NCC1CCOCC1 SDHGNNCYCXUKTQ-UHFFFAOYSA-N 0.000 description 1
- IYKBEOXZYPPJCM-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-(piperidin-4-ylmethyl)butanamide Chemical compound N1C2=CC(Cl)=CC=C2N=C1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)NCC1CCNCC1 IYKBEOXZYPPJCM-UHFFFAOYSA-N 0.000 description 1
- KJAZZYOZBPUDLE-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-[2-(dimethylamino)ethyl]-n-methylbutanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)N(C)CCN(C)C)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 KJAZZYOZBPUDLE-UHFFFAOYSA-N 0.000 description 1
- DEJXXVQJMXTPLQ-UHFFFAOYSA-N 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoic acid Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)O)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 DEJXXVQJMXTPLQ-UHFFFAOYSA-N 0.000 description 1
- HLPFMOOKIBJIQT-UHFFFAOYSA-N 4-(pyrrolidine-1-carbonyl)benzamide Chemical compound C1=CC(C(=O)N)=CC=C1C(=O)N1CCCC1 HLPFMOOKIBJIQT-UHFFFAOYSA-N 0.000 description 1
- SSVFRHRXPVMKDZ-UHFFFAOYSA-N 4-[2-(aminomethyl)pyrrolidine-1-carbonyl]-3-chloro-n-[1-(6-chloro-1h-benzimidazol-2-yl)ethyl]benzamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(C)NC(=O)C(C=C1Cl)=CC=C1C(=O)N1CCCC1CN SSVFRHRXPVMKDZ-UHFFFAOYSA-N 0.000 description 1
- QZOMOTSQDTVSFR-UHFFFAOYSA-N 4-[3-(aminomethyl)-5,6-dihydro-4H-cyclopenta[c]pyrazol-1-yl]-N-[(5-carbamimidoyl-2-hydroxyphenyl)methyl]-3-(trifluoromethyl)benzamide Chemical compound C1=2CCCC=2C(CN)=NN1C(C(=C1)C(F)(F)F)=CC=C1C(=O)NCC1=CC(C(N)=N)=CC=C1O QZOMOTSQDTVSFR-UHFFFAOYSA-N 0.000 description 1
- SIJWTCYOPDQSDX-UHFFFAOYSA-N 4-[4-[1-(6-chloro-1h-benzimidazol-2-yl)ethylamino]-6-methylquinoline-7-carbonyl]piperazin-2-one Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(C)NC(C1=CC=2C)=CC=NC1=CC=2C(=O)N1CCNC(=O)C1 SIJWTCYOPDQSDX-UHFFFAOYSA-N 0.000 description 1
- RSGDQMKQVSAEMO-JOCHJYFZSA-N 4-[acetyl(cyclopentyl)amino]-n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methylsulfanylethyl]-3-methylbenzamide Chemical compound N([C@H](CSC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1C)=CC=C1N(C(C)=O)C1CCCC1 RSGDQMKQVSAEMO-JOCHJYFZSA-N 0.000 description 1
- ZWGRFVIVQYBHJY-UHFFFAOYSA-N 4-hydroxy-3-[2-phenyl-1-[[7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]ethyl]benzenecarboximidamide Chemical compound NC(=N)C1=CC=C(O)C(C(CC=2C=CC=CC=2)NC=2C3=CC=C(C=C3N=CN=2)C(=O)N2CCCC2)=C1 ZWGRFVIVQYBHJY-UHFFFAOYSA-N 0.000 description 1
- ZOTPACDGKSMJRN-UHFFFAOYSA-N 4-hydroxy-3-[[[7-methoxy-6-(pyrrolidine-1-carbonyl)isoquinolin-1-yl]amino]methyl]benzenecarboximidamide Chemical compound N1=CC=C2C=C(C(=O)N3CCCC3)C(OC)=CC2=C1NCC1=CC(C(N)=N)=CC=C1O ZOTPACDGKSMJRN-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GPUHJPCLUJUQCD-UHFFFAOYSA-N 8-[4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoyl]-1-oxa-3,8-diazaspiro[4.5]decan-2-one Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)N(CC1)CCC21CNC(=O)O2 GPUHJPCLUJUQCD-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Chemical class 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- KDRBRQMQRZFBKA-UHFFFAOYSA-N N',4-dihydroxy-3-[[[6-methyl-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]methyl]benzenecarboximidamide Chemical compound N1=CN=C2C=C(C(=O)N3CCCC3)C(C)=CC2=C1NCC1=CC(C(=N)NO)=CC=C1O KDRBRQMQRZFBKA-UHFFFAOYSA-N 0.000 description 1
- ONXPDKGXOOORHB-BYPYZUCNSA-N N(5)-methyl-L-glutamine Chemical compound CNC(=O)CC[C@H](N)C(O)=O ONXPDKGXOOORHB-BYPYZUCNSA-N 0.000 description 1
- QQNVASVDTBYOPI-UHFFFAOYSA-N N-[(5-carbamimidoyl-2-hydroxyphenyl)methyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)NCC=2C(=CC=C(C=2)C(N)=N)O)=CC=C1C(=O)N1CCCC1 QQNVASVDTBYOPI-UHFFFAOYSA-N 0.000 description 1
- JZMTYDXWWYFOIV-UHFFFAOYSA-N N-[(5-carbamimidoyl-2-hydroxyphenyl)methyl]-4-(3-methyl-5,6-dihydro-4H-cyclopenta[c]pyrazol-1-yl)-3-(trifluoromethyl)benzamide Chemical compound C1=2CCCC=2C(C)=NN1C(C(=C1)C(F)(F)F)=CC=C1C(=O)NCC1=CC(C(N)=N)=CC=C1O JZMTYDXWWYFOIV-UHFFFAOYSA-N 0.000 description 1
- KOBZYVWAIIENIO-UHFFFAOYSA-N N-[1-[(5-carbamimidoyl-2-hydroxyphenyl)methylamino]-7-methylisoquinolin-6-yl]-N-cyclopentylacetamide Chemical compound C=1C2=CC=NC(NCC=3C(=CC=C(C=3)C(N)=N)O)=C2C=C(C)C=1N(C(=O)C)C1CCCC1 KOBZYVWAIIENIO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- YLMSXNRSXYNMJV-GXTWGEPZSA-N [(2r)-2-(aminomethyl)pyrrolidin-1-yl]-[6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]methanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCC[C@@H]1CN YLMSXNRSXYNMJV-GXTWGEPZSA-N 0.000 description 1
- CBRMMAPWXKYFOY-UHFFFAOYSA-N [(Z)-[amino-[4-hydroxy-3-[[[6-methyl-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]methyl]phenyl]methylidene]carbamoyl]oxymethyl acetate Chemical compound CC(=O)OCOC(=O)NC(=N)C1=CC=C(O)C(CNC=2C3=CC(C)=C(C(=O)N4CCCC4)C=C3N=CN=2)=C1 CBRMMAPWXKYFOY-UHFFFAOYSA-N 0.000 description 1
- GWOSHEGHIBUWTR-UHFFFAOYSA-N [4-[1-(6-chloro-1h-benzimidazol-2-yl)ethylamino]-6-methylquinolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(C)NC(C1=CC=2C)=CC=NC1=CC=2C(=O)N1CCCC1 GWOSHEGHIBUWTR-UHFFFAOYSA-N 0.000 description 1
- ZZHRRQMWVFZPLU-UUSAFJCLSA-N [4-[[(1s)-1-(6-bromo-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]-6-chloroquinazolin-7-yl]-(2,5-dihydro-1h-pyrrol-2-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC(Br)=CC=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)C1NCC=C1 ZZHRRQMWVFZPLU-UUSAFJCLSA-N 0.000 description 1
- IQKAOIBKAHJEBY-PIJUOJQZSA-N [4-[[(1s)-1-(6-bromo-1h-benzimidazol-2-yl)ethyl]amino]-6-chloroquinazolin-7-yl]-(2,5-dihydro-1h-pyrrol-2-yl)methanone Chemical compound N([C@@H](C)C=1NC2=CC(Br)=CC=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)C1NCC=C1 IQKAOIBKAHJEBY-PIJUOJQZSA-N 0.000 description 1
- OWFUOMYKGDFREB-HXUWFJFHSA-N [4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]-6-methoxyquinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2OC)=NC=NC1=CC=2C(=O)N1CC=CC1 OWFUOMYKGDFREB-HXUWFJFHSA-N 0.000 description 1
- WVUUBWGNSHRFJO-HWYAHNCWSA-N [4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]-6-methylquinazolin-7-yl]-(1,3-thiazolidin-2-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2C)=NC=NC1=CC=2C(=O)C1NCCS1 WVUUBWGNSHRFJO-HWYAHNCWSA-N 0.000 description 1
- WVBUFIWRIFMHHI-UHFFFAOYSA-N [4-[[1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]-6-methylquinolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCSC)NC(C1=CC=2C)=CC=NC1=CC=2C(=O)N1CCCC1 WVBUFIWRIFMHHI-UHFFFAOYSA-N 0.000 description 1
- NZRCKCNDRZSXHM-ZZWBGTBQSA-N [6-bromo-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]amino]quinazolin-7-yl]-(1,3-thiazolidin-2-yl)methanone Chemical compound N([C@H](COC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Br)=NC=NC1=CC=2C(=O)C1NCCS1 NZRCKCNDRZSXHM-ZZWBGTBQSA-N 0.000 description 1
- IKMZDHWOYWYJTR-LBPRGKRZSA-N [6-bromo-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Br)=NC=NC1=CC=2C(=O)N1CC=CC1 IKMZDHWOYWYJTR-LBPRGKRZSA-N 0.000 description 1
- YIXULUKTIICPNC-IBGZPJMESA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfanylpropyl]amino]quinazolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](CCSC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 YIXULUKTIICPNC-IBGZPJMESA-N 0.000 description 1
- ZBLDZSBGMXPXNY-IBGZPJMESA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methylsulfonylpropyl]amino]quinazolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](CCS(=O)(=O)C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 ZBLDZSBGMXPXNY-IBGZPJMESA-N 0.000 description 1
- PULJCUHABQICCL-IBGZPJMESA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)butyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@@H](CCC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 PULJCUHABQICCL-IBGZPJMESA-N 0.000 description 1
- WQUXFWRNMWSHNO-NSHDSACASA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]-(1,3-thiazolidin-3-yl)methanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCSC1 WQUXFWRNMWSHNO-NSHDSACASA-N 0.000 description 1
- KRKQMWHVCXTIFN-LBPRGKRZSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]-(2,5-dihydropyrrol-1-yl)methanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CC=CC1 KRKQMWHVCXTIFN-LBPRGKRZSA-N 0.000 description 1
- WLYWOHREUVJHNO-LBPRGKRZSA-N [6-chloro-4-[[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]amino]quinazolin-7-yl]-pyrrolidin-1-ylmethanone Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 WLYWOHREUVJHNO-LBPRGKRZSA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940000279 aggrastat Drugs 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- CEMPRUFIGKWFHT-SANMLTNESA-N benzyl (4s)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[3-methyl-4-(pyrrolidine-1-carbonyl)benzoyl]amino]butanoate Chemical compound CC1=CC(C(=O)N[C@@H](CCC(=O)OCC=2C=CC=CC=2)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 CEMPRUFIGKWFHT-SANMLTNESA-N 0.000 description 1
- TVRYMMKZRZBXBH-VWLOTQADSA-N benzyl (4s)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoate Chemical compound C([C@@H](C=1NC2=CC=C(C=C2N=1)Cl)NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CC(=O)OCC1=CC=CC=C1 TVRYMMKZRZBXBH-VWLOTQADSA-N 0.000 description 1
- TVRYMMKZRZBXBH-UHFFFAOYSA-N benzyl 4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoate Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(NC=1C2=CC(Cl)=C(C(=O)N3CCCC3)C=C2N=CN=1)CCC(=O)OCC1=CC=CC=C1 TVRYMMKZRZBXBH-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000638 benzylaminocarbonyl group Chemical group C(C1=CC=CC=C1)NC(=O)* 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 229960004969 dalteparin Drugs 0.000 description 1
- 229960003828 danaparoid Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229960004468 eptifibatide Drugs 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VXLJQDPUTFXYCN-FQEVSTJZSA-N ethyl (4s)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanoate Chemical compound N([C@@H](CCC(=O)OCC)C=1NC2=CC=C(Cl)C=C2N=1)C(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 VXLJQDPUTFXYCN-FQEVSTJZSA-N 0.000 description 1
- LRWGVMYWXLXPTR-UHFFFAOYSA-N ethyl 2-(3-carbamimidoylphenyl)-2-[[3-methyl-4-(pyrrolidine-1-carbonyl)benzoyl]amino]acetate Chemical compound C=1C=CC(C(N)=N)=CC=1C(C(=O)OCC)NC(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 LRWGVMYWXLXPTR-UHFFFAOYSA-N 0.000 description 1
- IKZACQMAVUIGPY-HOTGVXAUSA-N fradafiban Chemical compound C1=CC(C(=N)N)=CC=C1C(C=C1)=CC=C1OC[C@H]1NC(=O)[C@H](CC(O)=O)C1 IKZACQMAVUIGPY-HOTGVXAUSA-N 0.000 description 1
- 229950008851 fradafiban Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Chemical class 0.000 description 1
- 229940056984 integrilin Drugs 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical class OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 1
- 125000004254 isoquinolin-1-yl group Chemical group [H]C1=C([H])C2=C([H])C([H])=C([H])C([H])=C2C(*)=N1 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- PGCFXITVMNNKON-ROUUACIJSA-N lefradafiban Chemical compound N1C(=O)[C@H](CC(=O)OC)C[C@H]1COC1=CC=C(C=2C=CC(=CC=2)C(=N)NC(=O)OC)C=C1 PGCFXITVMNNKON-ROUUACIJSA-N 0.000 description 1
- 229950011635 lefradafiban Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- NMJORVOYSJLJGU-UHFFFAOYSA-N methane clathrate Chemical compound C.C.C.C.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O NMJORVOYSJLJGU-UHFFFAOYSA-N 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- FMSAVQSHZTZMTE-UHFFFAOYSA-N n-(2-aminoethyl)-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]butanamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CCC(=O)NCCN)NC(C1=CC=2Cl)=NC=NC1=CC=2C(=O)N1CCCC1 FMSAVQSHZTZMTE-UHFFFAOYSA-N 0.000 description 1
- KQORXQUOVZHIOJ-IBGZPJMESA-N n-[(1r)-1-(6-chloro-1h-benzimidazol-2-yl)-2-hydroxyethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CO)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 KQORXQUOVZHIOJ-IBGZPJMESA-N 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- IIBIOFPXPWCQOI-FQEVSTJZSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-3-methoxypropyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](CCOC)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 IIBIOFPXPWCQOI-FQEVSTJZSA-N 0.000 description 1
- IMLFGSRQQSSZCW-QHCPKHFHSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)-4-(1,1-dioxo-1,4-thiazinan-4-yl)-4-oxobutyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)N[C@@H](CCC(=O)N2CCS(=O)(=O)CC2)C=2NC3=CC(Cl)=CC=C3N=2)=CC=C1C(=O)N1CCCC1 IMLFGSRQQSSZCW-QHCPKHFHSA-N 0.000 description 1
- YHRXFEUHRJIWLH-AWEZNQCLSA-N n-[(1s)-1-(6-chloro-1h-benzimidazol-2-yl)ethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N([C@@H](C)C=1NC2=CC=C(Cl)C=C2N=1)C(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 YHRXFEUHRJIWLH-AWEZNQCLSA-N 0.000 description 1
- RUHMXJKQXZYSIF-UHFFFAOYSA-N n-[(6-chloro-1h-benzimidazol-2-yl)-phenylmethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CC1=CC(C(=O)NC(C=2NC3=CC=C(Cl)C=C3N=2)C=2C=CC=CC=2)=CC=C1C(=O)N1CCCC1 RUHMXJKQXZYSIF-UHFFFAOYSA-N 0.000 description 1
- AQKCVIJGQHMSEJ-UHFFFAOYSA-N n-[1-(6-bromo-1h-benzimidazol-2-yl)ethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N=1C2=CC(Br)=CC=C2NC=1C(C)NC(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 AQKCVIJGQHMSEJ-UHFFFAOYSA-N 0.000 description 1
- NYFNPJJDRQUKJO-UHFFFAOYSA-N n-[1-(6-chloro-1h-benzimidazol-2-yl)-2-methoxyethyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(COC)NC(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 NYFNPJJDRQUKJO-UHFFFAOYSA-N 0.000 description 1
- NIRFBYFEHNCWDS-UHFFFAOYSA-N n-[1-(6-chloro-1h-benzimidazol-2-yl)-3-methylbutyl]-3-methyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound N=1C2=CC(Cl)=CC=C2NC=1C(CC(C)C)NC(=O)C(C=C1C)=CC=C1C(=O)N1CCCC1 NIRFBYFEHNCWDS-UHFFFAOYSA-N 0.000 description 1
- XSXSXHGFTUXHHS-UHFFFAOYSA-N n-[1-(6-chloro-1h-benzimidazol-2-yl)ethyl]-3-ethyl-4-(pyrrolidine-1-carbonyl)benzamide Chemical compound CCC1=CC(C(=O)NC(C)C=2NC3=CC=C(Cl)C=C3N=2)=CC=C1C(=O)N1CCCC1 XSXSXHGFTUXHHS-UHFFFAOYSA-N 0.000 description 1
- FHJXLZNEZIIVMV-UHFFFAOYSA-N n-[3-bromo-4-(pyrrolidine-1-carbonyl)phenyl]-2-(3-carbamimidoylphenyl)-3-pyridin-4-ylpropanamide Chemical compound NC(=N)C1=CC=CC(C(CC=2C=CN=CC=2)C(=O)NC=2C=C(Br)C(C(=O)N3CCCC3)=CC=2)=C1 FHJXLZNEZIIVMV-UHFFFAOYSA-N 0.000 description 1
- MXSUKUHNZNKHBL-UHFFFAOYSA-N n-[4-bromo-2-[(5-chloropyridin-2-yl)carbamoyl]-6-hydroxyphenyl]-1-propan-2-ylpiperidine-4-carboxamide Chemical compound C1CN(C(C)C)CCC1C(=O)NC1=C(O)C=C(Br)C=C1C(=O)NC1=CC=C(Cl)C=N1 MXSUKUHNZNKHBL-UHFFFAOYSA-N 0.000 description 1
- VDRVPWCWCAMGPB-UHFFFAOYSA-N n-benzyl-4-(6-chloro-1h-benzimidazol-2-yl)-4-[[6-chloro-7-(pyrrolidine-1-carbonyl)quinazolin-4-yl]amino]-n-methylbutanamide Chemical compound N=1C=NC2=CC(C(=O)N3CCCC3)=C(Cl)C=C2C=1NC(C=1NC2=CC(Cl)=CC=C2N=1)CCC(=O)N(C)CC1=CC=CC=C1 VDRVPWCWCAMGPB-UHFFFAOYSA-N 0.000 description 1
- 229960000899 nadroparin Drugs 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002942 palmitic acid derivatives Chemical class 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 229960004923 phenprocoumon Drugs 0.000 description 1
- DQDAYGNAKTZFIW-UHFFFAOYSA-N phenprocoumon Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC)C1=CC=CC=C1 DQDAYGNAKTZFIW-UHFFFAOYSA-N 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 125000005547 pivalate group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229940020573 plavix Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 1
- 230000036515 potency Effects 0.000 description 1
- IVYHFJFVBLEKDG-PGUFJCEWSA-N propyl 2-[[(2r)-2-[2-[[4-(n'-benzoylcarbamimidoyl)anilino]methyl]-1-methylbenzimidazol-5-yl]-1-oxo-1-pyrrolidin-1-ylpropan-2-yl]amino]acetate Chemical compound O=C([C@](C)(NCC(=O)OCCC)C=1C=C2N=C(CNC=3C=CC(=CC=3)C(=N)NC(=O)C=3C=CC=CC=3)N(C)C2=CC=1)N1CCCC1 IVYHFJFVBLEKDG-PGUFJCEWSA-N 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 229950010535 razaxaban Drugs 0.000 description 1
- 229940107685 reopro Drugs 0.000 description 1
- 229960001148 rivaroxaban Drugs 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960005062 tinzaparin Drugs 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05006711 | 2005-03-29 | ||
| PCT/EP2006/061046 WO2006103206A2 (en) | 2005-03-29 | 2006-03-27 | Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0608656A2 true BRPI0608656A2 (pt) | 2010-01-19 |
Family
ID=36423564
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0608656-0A BRPI0608656A2 (pt) | 2005-03-29 | 2006-03-27 | composiÇÕes farmacÊuticas para tratamento de trombose |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20060222640A1 (https=) |
| EP (1) | EP1885354A2 (https=) |
| JP (1) | JP2008534552A (https=) |
| KR (1) | KR20070116936A (https=) |
| CN (1) | CN101151030A (https=) |
| AR (1) | AR056291A1 (https=) |
| AU (1) | AU2006228600A1 (https=) |
| BR (1) | BRPI0608656A2 (https=) |
| CA (1) | CA2602563A1 (https=) |
| CL (1) | CL2010000395A1 (https=) |
| EA (1) | EA015122B1 (https=) |
| IL (1) | IL186267A0 (https=) |
| MX (1) | MX2007010664A (https=) |
| NO (1) | NO20074149L (https=) |
| NZ (1) | NZ562775A (https=) |
| TW (1) | TW200722089A (https=) |
| UA (1) | UA92603C2 (https=) |
| WO (1) | WO2006103206A2 (https=) |
| ZA (1) | ZA200706698B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8906894B1 (en) | 2000-07-27 | 2014-12-09 | Thomas N. Thomas | Methods for preventing and treating thrombotic disorders |
| US20030181488A1 (en) | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
| DE10339862A1 (de) * | 2003-08-29 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
| IL159273A0 (en) * | 2003-12-09 | 2004-06-01 | Transpharma Medical Ltd | Transdermal delivery system for sustained release of polypeptides |
| US20080274166A1 (en) * | 2005-06-10 | 2008-11-06 | Transpharma Medical Ltd. | Patch for Transdermal Drug Delivery |
| AR062057A1 (es) * | 2006-07-17 | 2008-10-15 | Boehringer Ingelheim Int | Uso de los inhibidores directos de la trombina |
| WO2008043759A1 (en) * | 2006-10-10 | 2008-04-17 | Boehringer Ingelheim International Gmbh | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
| DE102006051625A1 (de) | 2006-11-02 | 2008-05-08 | Bayer Materialscience Ag | Kombinationstherapie substituierter Oxazolidinone |
| CA2704164A1 (en) * | 2007-10-29 | 2009-05-07 | Transpharma Medical Ltd. | Vertical patch drying |
| WO2010013231A2 (en) * | 2008-07-29 | 2010-02-04 | Yeda Research And Development Co. Ltd. | Modulation of coagulation factors and effectors of same for control of transplant organ size |
| WO2010029552A1 (en) * | 2008-09-10 | 2010-03-18 | Transpharma Medical Ltd. | Transdermal delivery of oligosaccharides |
| JP2013510072A (ja) | 2008-11-11 | 2013-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 従来のワルファリン治療に対して安全性プロフィールが改善されたダビガトランエテキシレートまたはその塩を使用して血栓症を治療または予防するための方法 |
| CN102209546A (zh) * | 2008-11-11 | 2011-10-05 | 贝林格尔.英格海姆国际有限公司 | 使用达比加群酯或其盐治疗或预防血栓形成且与常规的华法林疗法相比具有改良有效性的方法 |
| AR074108A1 (es) * | 2008-11-11 | 2010-12-22 | Boehringer Ingelheim Int | Metodo para tratar o prevenir la trombosis utilizando etexilato de dabigatran o una sal del mismo con eficacia mejorada sobre la terapia convencional con warfarina |
| RU2011132125A (ru) | 2008-12-30 | 2013-02-10 | Тромбологик Апс | Способы идентификации критических пациентов с повышенным риском развития органной недостаточности и соединения для их лечения |
| JP6012629B2 (ja) * | 2011-01-25 | 2016-10-25 | ユニヴェルシテ カソリック ド ルーヴァンＵｎｉｖｅｒｓｉｔｅ Ｃａｔｈｏｌｉｑｕｅ Ｄｅ Ｌｏｕｖａｉｎ | 細胞移植のための組成物および方法 |
| CN102250099B (zh) * | 2011-05-16 | 2013-10-16 | 中国药科大学 | 一类非肽类抗凝血酶抑制剂、其制法以及医药用途 |
| EP2806879B1 (en) | 2012-01-25 | 2019-03-06 | Université Catholique de Louvain | Compositions and methods for cell transplantation |
| US20130345262A1 (en) | 2012-06-25 | 2013-12-26 | Boehringer Ingelheim International Gmbh | Method for prevention of stroke |
| EP2722033A1 (en) * | 2012-10-19 | 2014-04-23 | Sanovel Ilac Sanayi ve Ticaret A.S. | Pharmaceutical Compositions of Dabigatran Free Base |
| EP2722034B1 (en) * | 2012-10-19 | 2020-09-16 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral pharmaceutical formulations comprising dabigatran |
| ES2759228T3 (es) | 2013-07-05 | 2020-05-08 | Univ Catholique Louvain | Medio acondicionado de células madre de hígado de adultos y su uso en el tratamiento de trastornos del hígado |
| DE102014108210A1 (de) * | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| CN105250286A (zh) * | 2015-11-13 | 2016-01-20 | 谭惠娟 | 一种抗血栓组合物 |
| CN108236612A (zh) * | 2016-12-27 | 2018-07-03 | 李志忠 | 用于冠脉介入手术中抗凝的组合产品及其用途 |
| US12251377B2 (en) | 2019-03-06 | 2025-03-18 | University Of Rochester | Anticoagulant compositions and uses thereof |
| US11654036B2 (en) | 2020-05-26 | 2023-05-23 | Elixir Medical Corporation | Anticoagulant compounds and methods and devices for their use |
| CN115192691B (zh) * | 2022-08-31 | 2025-03-04 | 晓恩医药包装材料(安庆)有限公司 | 一种阿加曲班注射液及预灌封注射器 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6087380A (en) * | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
| US5510330A (en) * | 1994-03-25 | 1996-04-23 | Boehringer Mannheim Gmbh | Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof. |
| NZ286082A (en) * | 1995-03-15 | 1998-09-24 | Behringwerke Ag | Method of treating acute myocardial infarction with hirudin and acetylsalicylic acid in patients not undergoing thrombolytic treatment |
| FR2744918B1 (fr) * | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
| US6414008B1 (en) * | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
| DE19834751A1 (de) * | 1998-08-01 | 2000-02-03 | Boehringer Ingelheim Pharma | Disubstituierte bicyclische Heterocyclen, ihre Herstellung und ihre Verwendung als Arzneimittel |
| GB9930540D0 (en) * | 1999-12-23 | 2000-02-16 | Rhone Poulenc Rorer Pharma | Chemical compounds |
| GB0014134D0 (en) * | 2000-06-10 | 2000-08-02 | Astrazeneca Ab | Combination therapy |
| KR20040044514A (ko) * | 2001-09-14 | 2004-05-28 | 미쯔비시 웰 파마 가부시키가이샤 | 항혈전약과 피라졸론 유도체의 조합 약제 |
| KR101005716B1 (ko) * | 2002-03-07 | 2011-01-05 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | ３－［（２－｛［４－（헥실옥시카보닐아미노－이미노-메틸）－페닐아미노］－메틸｝－１－메틸－１ｈ－벤즈이미다졸－５－카보닐）－피리딘－２－일－아미노］ 프로피온산 에틸에스테르의 경구 투여 형태 |
| DE10235639A1 (de) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel |
| AU2004231306A1 (en) * | 2003-04-24 | 2004-11-04 | Boehringer Ingelheim International Gmbh | Use of dipyridamole or mopidamole for treatment and prevention of thrombo-embolic diseases and disorders caused by excessive formation of thrombin and/or by elevated expression of thrombin receptors |
-
2006
- 2006-03-26 US US11/277,503 patent/US20060222640A1/en not_active Abandoned
- 2006-03-27 MX MX2007010664A patent/MX2007010664A/es not_active Application Discontinuation
- 2006-03-27 EP EP06725316A patent/EP1885354A2/en not_active Withdrawn
- 2006-03-27 UA UAA200711762A patent/UA92603C2/ru unknown
- 2006-03-27 KR KR1020077024953A patent/KR20070116936A/ko not_active Ceased
- 2006-03-27 WO PCT/EP2006/061046 patent/WO2006103206A2/en not_active Ceased
- 2006-03-27 JP JP2008503489A patent/JP2008534552A/ja active Pending
- 2006-03-27 NZ NZ562775A patent/NZ562775A/en unknown
- 2006-03-27 AU AU2006228600A patent/AU2006228600A1/en not_active Abandoned
- 2006-03-27 CN CNA2006800108359A patent/CN101151030A/zh active Pending
- 2006-03-27 EA EA200701841A patent/EA015122B1/ru not_active IP Right Cessation
- 2006-03-27 CA CA002602563A patent/CA2602563A1/en not_active Abandoned
- 2006-03-27 BR BRPI0608656-0A patent/BRPI0608656A2/pt not_active IP Right Cessation
- 2006-03-28 TW TW095110732A patent/TW200722089A/zh unknown
- 2006-03-29 AR ARP060101205A patent/AR056291A1/es unknown
-
2007
- 2007-08-10 NO NO20074149A patent/NO20074149L/no not_active Application Discontinuation
- 2007-08-13 ZA ZA200706698A patent/ZA200706698B/xx unknown
- 2007-09-25 IL IL186267A patent/IL186267A0/en unknown
-
2010
- 2010-03-19 US US12/727,933 patent/US20100184729A1/en not_active Abandoned
- 2010-04-21 CL CL2010000395A patent/CL2010000395A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006103206A2 (en) | 2006-10-05 |
| US20100184729A1 (en) | 2010-07-22 |
| IL186267A0 (en) | 2008-01-20 |
| CL2010000395A1 (es) | 2010-08-20 |
| JP2008534552A (ja) | 2008-08-28 |
| WO2006103206A3 (en) | 2007-01-11 |
| US20060222640A1 (en) | 2006-10-05 |
| TW200722089A (en) | 2007-06-16 |
| CN101151030A (zh) | 2008-03-26 |
| NZ562775A (en) | 2011-03-31 |
| EA015122B1 (ru) | 2011-06-30 |
| KR20070116936A (ko) | 2007-12-11 |
| MX2007010664A (es) | 2007-12-12 |
| NO20074149L (no) | 2007-12-11 |
| EA200701841A1 (ru) | 2008-02-28 |
| AR056291A1 (es) | 2007-10-03 |
| EP1885354A2 (en) | 2008-02-13 |
| UA92603C2 (ru) | 2010-11-25 |
| AU2006228600A1 (en) | 2006-10-05 |
| CA2602563A1 (en) | 2006-10-05 |
| ZA200706698B (en) | 2008-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0608656A2 (pt) | composiÇÕes farmacÊuticas para tratamento de trombose | |
| EP3788039B1 (en) | Factor xiia inhibitors | |
| US20250115606A1 (en) | Heterocyclic glp-1 agonists | |
| JP2023546054A (ja) | ヘテロ環ｇｌｐ－１アゴニスト | |
| ES2600783T3 (es) | Régimen de dosificación de edoxabán | |
| JP2011252012A (ja) | シクロペプチドおよび化学治療剤または血管新生阻害剤を含有する医薬製剤 | |
| BRPI0715492A2 (pt) | uso de inibidores diretos de trombina | |
| KR20170095845A (ko) | 디히드로인돌리지논 유도체 | |
| US20210261524A1 (en) | Therapeutic compounds and compositions | |
| US9539218B2 (en) | Prevention and treatment of thromboembolic disorders | |
| TW200812619A (en) | TRA combination therapies | |
| TW201302203A (zh) | Ａ２b腺苷受體拮抗劑於在心肌梗塞後之病患內治療心衰竭及心律不整上之用途 | |
| BR112019020754A2 (pt) | métodos de prevenção ou tratamento de doenças oftalmológicas | |
| CN101743244B (zh) | 取代的*唑烷酮类及其用途 | |
| EP3320904B1 (en) | Preventative and/or therapeutic agent containing pyridyl aminoacetic acid compound for treating a disease involving a greatly elevated intraocular pressure | |
| JP2013500298A (ja) | 高齢かつ腎障害の非ｓｔ上昇型心筋梗塞患者の処置のためのオタミキサバン | |
| CN111902404A (zh) | 治疗化合物和组合物 | |
| WO2022238884A1 (en) | Dosing regimens | |
| US20080139614A1 (en) | Treatment Of Stroke With Histamine H3 Inverse Agonists Or Histamine H3 Antagonists | |
| SK282353B6 (sk) | Farmaceutický prostriedok na intravenózne podanie | |
| HK1119932A (en) | Combinations comprising at least one direct thrombin inhibitor for the treatment of thrombosis | |
| RU2813780C2 (ru) | Терапевтические соединения и композиции | |
| JP2010524871A (ja) | 肺高血圧の処置および予防のためのオキサゾリジノン類 | |
| HK1235292A1 (en) | Prophylactic or therapeutic agent for diseases of posterior segment of eye | |
| JP2016029037A (ja) | 後眼部疾患の予防または治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUI DADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2211 DE 21/05/2013. |